| scholarly article | Q13442814 |
| editorial | Q871232 |
| P50 | author | Nora Volkow | Q457967 |
| P2860 | cites work | A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors | Q22251463 |
| Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study | Q28259349 | ||
| A neurobiological basis for substance abuse comorbidity in schizophrenia | Q28347063 | ||
| Cognitive effects of nicotine | Q32077222 | ||
| Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia | Q33932087 | ||
| Serious mental illness and tobacco addiction: a model program to address this common but neglected issue | Q35559018 | ||
| Behavioral interventions for dual-diagnosis patients | Q35953868 | ||
| Ionotropic and metabotropic glutamate receptor structure and pharmacology | Q36054635 | ||
| Cannabis use and misuse prevalence among people with psychosis | Q36274751 | ||
| Further evidence of differences in substance use and dependence between Australia and the United States | Q37276885 | ||
| Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify "connectivity constellation" and drug target genes with pleiotropic effects | Q37320742 | ||
| Schizophrenia: a neural diathesis-stress model | Q41616625 | ||
| Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders | Q44041615 | ||
| Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder | Q44381605 | ||
| Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions | Q44752429 | ||
| The element of surprise | Q46143379 | ||
| Smoking and schizophrenia: epidemiological and clinical features | Q46536785 | ||
| The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems | Q46772825 | ||
| Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement | Q46899798 | ||
| Patterns of current and lifetime substance use in schizophrenia | Q48715154 | ||
| Substance abuse-related mortality among middle-aged male VA psychiatric patients. | Q51893250 | ||
| Double jeopardy: schizophrenia and substance use. | Q51974228 | ||
| Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. | Q51990041 | ||
| Non-random relation between drugs of abuse and psychiatric diagnosis | Q52111266 | ||
| Substance use in a population-based clinic sample of people with first-episode psychosis | Q57773718 | ||
| Substance use: a powerful predictor of relapse in schizophrenia | Q71505986 | ||
| Diagnosis and management of substance use disorders among inpatients with schizophrenia | Q74097997 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| comorbidity | Q1414874 | ||
| P304 | page(s) | 469-472 | |
| P577 | publication date | 2009-03-26 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Substance use disorders in schizophrenia--clinical implications of comorbidity | |
| P478 | volume | 35 |
| Q30417841 | Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice |
| Q48016709 | Additive Effect of Cigarette Smoking on Gray Matter Abnormalities in Schizophrenia. |
| Q48908840 | An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses |
| Q49870570 | Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach |
| Q39413679 | Antipsychotic drugs: From receptor-binding profiles to metabolic side effects |
| Q58714618 | Assessment of Cognition in Schizophrenia Using Trail Making Test: A Meta-Analysis |
| Q37172408 | Associations between Polygenic Risk for Psychiatric Disorders and Substance Involvement |
| Q91867577 | Attitudes of Italian Psychiatrists Toward the Evaluation of Physical Comorbidities and Sexual Dysfunction in Patients With Schizophrenia. Implications for Clinical Practice |
| Q38747027 | Behavioral predictors of alcohol drinking in a neurodevelopmental rat model of schizophrenia and co-occurring alcohol use disorder |
| Q37760933 | Beyond the first episode: candidate factors for a risk prediction model of schizophrenia |
| Q94503123 | Cannabis Use in Inpatients With Schizophrenia Spectrum Disorders at a Community Hospital |
| Q33834127 | Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis |
| Q36666842 | Cannabis withdrawal in chronic cannabis users with schizophrenia |
| Q36920503 | Characterizing the longitudinal patterns of substance use among individuals diagnosed with serious mental illness after psychiatric hospitalization |
| Q31161373 | Characterizing white matter changes in chronic schizophrenia: A free-water imaging multi-site study |
| Q55502857 | Clinical implication of smoking among patients with schizophrenia at a Tertiary Institution in South East Nigeria. |
| Q36452922 | Cognitive Enhancement Therapy Improves Frontolimbic Regulation of Emotion in Alcohol and/or Cannabis Misusing Schizophrenia: A Preliminary Study |
| Q35019827 | Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q37691329 | Cortical and sub-cortical effects in primate models of cocaine use: implications for addiction and the increased risk of psychiatric illness |
| Q39019384 | DISC1 signaling in cocaine addiction: Towards molecular mechanisms of co-morbidity. |
| Q36520152 | DNA Repair Gene (XRCC1) Polymorphism (Arg399Gln) Associated with Schizophrenia in South Indian Population: A Genotypic and Molecular Dynamics Study. |
| Q92541706 | Determining factors for Cannabis use among Moroccans Schizophrenic Patients: A cross sectional study |
| Q92642814 | Dopamine D1 Receptor (D1R) Expression Is Controlled by a Transcriptional Repressor Complex Containing DISC1 |
| Q38795449 | Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population |
| Q45037990 | Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. |
| Q47995206 | Family interventions in Schizophrenia: promise and pitfalls over 30 years |
| Q35839691 | GABRB2 Haplotype Association with Heroin Dependence in Chinese Population |
| Q24289498 | Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findings |
| Q57032352 | Genome-wide association study identifies glutamate ionotropic receptor GRIA4 as a risk gene for comorbid nicotine dependence and major depression |
| Q38813132 | Gestalt Therapy Applied: A Case Study with an Inpatient Diagnosed with Substance Use and Bipolar Disorders |
| Q64999981 | Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia. |
| Q37719233 | Impact of substance use disorder on presentation and short-term course of schizophrenia |
| Q36817270 | Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts |
| Q50580794 | Increased temporal discounting after chronic stress in CHL1-deficient mice is reversed by 5-HT2C agonist Ro 60-0175. |
| Q34377871 | Is schizophrenia a dopamine supersensitivity psychotic reaction? |
| Q38903556 | L-type Ca2+ channels in mood, cognition and addiction: integrating human and rodent studies with a focus on behavioural endophenotypes |
| Q30409196 | MicroRNAs in addiction: adaptation's middlemen? |
| Q45978207 | Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia. |
| Q35046489 | Mutant DISC1 affects methamphetamine-induced sensitization and conditioned place preference: a comorbidity model. |
| Q33762494 | Neurocognitive functioning of individuals with schizophrenia: using and not using drugs |
| Q37565145 | Nicotine is more addictive, not more cognitively therapeutic in a neurodevelopmental model of schizophrenia produced by neonatal ventral hippocampal lesions |
| Q40600955 | Opioid abuse and hospitalization rates in patients with schizophrenia |
| Q36815675 | Patterns of Substance Use During Cognitive Enhancement Therapy: An 18-Month Randomized Feasibility Study |
| Q37309718 | Peripheral endocannabinoid system dysregulation in first-episode psychosis |
| Q34256300 | Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy |
| Q51899658 | Predictors of psychosis severity in individuals with primary stimulant addictions |
| Q36580033 | Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers |
| Q38996589 | Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders |
| Q37239425 | Psychiatric comorbidity among adults with schizophrenia: a latent class analysis |
| Q90734187 | Psychoactive substance use among outpatients with severe mental illness: A comparative study |
| Q38862631 | Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of schizophrenia in male and female rats |
| Q37244113 | Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia |
| Q34217410 | Risk and protective factors for relapse among individuals with schizophrenia: a qualitative study in Dar es Salaam, Tanzania |
| Q47577874 | Substance use among Danish psychiatric patients: a cross-sectional study. |
| Q37052393 | Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy |
| Q67223779 | The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review |
| Q48128372 | The adolescent brain at risk for substance use disorders: a review of functional MRI research on motor response inhibition |
| Q33641039 | The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample |
| Q38729376 | The link between schizophrenia and substance use disorder: A unifying hypothesis |
| Q43939799 | The prevalence of substance use among psychiatric patients: the case study of Bugando Medical centre, Mwanza (northern Tanzania). |
| Q36252902 | The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data. |
| Q50594262 | The substance use among forensic psychiatric patients. |
| Q38718345 | Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries |
| Q41975077 | Toward early estimation and treatment of addiction vulnerability: radial arm maze and N-acetyl cysteine before cocaine sensitization or nicotine self-administration in neonatal ventral hippocampal lesion rats |
| Q45767391 | Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors |
| Q30362464 | nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. |
Search more.